

Stephen R Durham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10605638/publications.pdf>

Version: 2024-02-01

88
papers

16,059
citations

31976
53
h-index

54911
84
g-index

88
all docs

88
docs citations

88
times ranked

8332
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468. | 5.7 | 39 |
| 2 | Immunotherapy for Allergy. , 2022, , 491-502. | | 0 |
| 3 | Allergen immunotherapy for long-term tolerance and prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 802-811. | 2.9 | 21 |
| 4 | Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 292-298. | 2.2 | 14 |
| 5 | Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 663-676. | 2.9 | 34 |
| 6 | Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7. | 14.3 | 134 |
| 7 | Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1061-1071.e11. | 2.9 | 41 |
| 8 | Immunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1769-1778. | 3.8 | 52 |
| 9 | Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 599083. | 4.8 | 68 |
| 10 | Allergen Immunotherapy in Children Userâ€™s Guide. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 1-101. | 2.6 | 169 |
| 11 | Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1067-1076. | 2.9 | 90 |
| 12 | Immunologic mechanisms of a short-course of <i>Lolium perenne</i> peptide immunotherapy: A randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 738-749. | 2.9 | 35 |
| 13 | Duration of allergen immunotherapy for inhalant allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 594-605. | 2.3 | 32 |
| 14 | Synchronous immune alterations mirror clinical response during allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1750-1760.e1. | 2.9 | 61 |
| 15 | UK Immunotherapy Study: Reanalysis by a combined symptom and medication score. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1998-1999.e3. | 2.9 | 6 |
| 16 | Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. <i>Current Treatment Options in Allergy</i> , 2018, 5, 275-290. | 2.2 | 58 |
| 17 | New approaches to allergen immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 293-305. | 1.0 | 54 |
| 18 | Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 52-57. | 3.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 615. | 7.4 | 166 |
| 20 | Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1485-1498. | 2.9 | 323 |
| 21 | Intradermal grass pollen immunotherapy increases T H 2 and IgE responses and worsens respiratory allergic symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1830-1839.e13. | 2.9 | 35 |
| 22 | Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 73-86. | 2.6 | 67 |
| 23 | Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1081-1088.e4. | 2.9 | 64 |
| 24 | Asthma phenotypes and IgE responses. <i>European Respiratory Journal</i> , 2016, 47, 304-319. | 6.7 | 197 |
| 25 | Sublingual or subcutaneous immunotherapy for allergic rhinitis?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 339-349.e10. | 2.9 | 169 |
| 26 | Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 452-461.e9. | 2.9 | 48 |
| 27 | IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1249-1256. | 2.9 | 207 |
| 28 | Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 913-921.e9. | 2.9 | 101 |
| 29 | Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. <i>Thorax</i> , 2014, 69, 335-345. | 5.6 | 13 |
| 30 | Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 468-475.e6. | 2.9 | 375 |
| 31 | Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 872-879.e7. | 2.9 | 110 |
| 32 | Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1543-1556. | 3.1 | 68 |
| 33 | Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). <i>Clinical and Translational Allergy</i> , 2013, 3, 27. | 3.2 | 6 |
| 34 | IL-22 suppresses IFN- γ -mediated lung inflammation in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 562-570. | 2.9 | 79 |
| 35 | Allergen Immunotherapy and Tolerance. <i>Allergology International</i> , 2013, 62, 403-413. | 3.3 | 88 |
| 36 | A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype. <i>Journal of Immunology</i> , 2013, 190, 3068-3078. | 0.8 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Allergen immunotherapy for allergic respiratory diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1499-1512. | 3.3 | 38 |
| 38 | EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 20. | 3.2 | 97 |
| 39 | Allergen Immunotherapy: A Centenary Celebration. <i>World Allergy Organization Journal</i> , 2011, 4, 104-106. | 3.5 | 13 |
| 40 | Mechanisms of Sublingual Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 191-209. | 1.9 | 26 |
| 41 | Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 30-38. | 2.9 | 168 |
| 42 | The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: AAGlobal Allergy and Asthma European Network (GA2LEN) article. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 49-56.e11. | 2.9 | 42 |
| 43 | One hundred years of allergen immunotherapy: Time to ring the changes. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 3-7. | 2.9 | 57 |
| 44 | Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 509-516.e5. | 2.9 | 299 |
| 45 | Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 311-323. | 1.9 | 37 |
| 46 | Long-term clinical and immunological effects of allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 586-593. | 2.3 | 76 |
| 47 | Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 131-138.e7. | 2.9 | 311 |
| 48 | Sublingual Immunotherapy: World Allergy Organization Position Paper 2009. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1-59. | 5.7 | 316 |
| 49 | Sub-Lingual Immunotherapy. <i>World Allergy Organization Journal</i> , 2009, 2, 233-281. | 3.5 | 100 |
| 50 | Allergic and Non-Allergic Rhinitis. , 2009, , 973-990. | | 8 |
| 51 | Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. <i>Journal of Clinical Investigation</i> , 2009, 119, 3573-85. | 8.2 | 840 |
| 52 | Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 512-518.e2. | 2.9 | 192 |
| 53 | Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1120-1125.e2. | 2.9 | 289 |
| 54 | Sublingual immunotherapy: what have we learnt from the "big trials"? <i>Current Opinion in Allergy and Clinical Immunology</i> , 2008, 8, 577-584. | 2.3 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2007, 119, 881-891. | 2.9 | 251 |
| 56 | Tradition and innovation: Finding the right balance. Journal of Allergy and Clinical Immunology, 2007, 119, 792-795. | 2.9 | 8 |
| 57 | Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. Journal of Allergy and Clinical Immunology, 2007, 120, 688-695. | 2.9 | 122 |
| 58 | Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study. Quality of Life Research, 2007, 16, 191-201. | 3.1 | 55 |
| 59 | Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology, 2006, 117, 319-325. | 2.9 | 353 |
| 60 | Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology, 2006, 117, 802-809. | 2.9 | 470 |
| 61 | Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology, 2006, 118, 434-440. | 2.9 | 415 |
| 62 | Allergen immunotherapy (desensitisation) for allergic diseases. Clinical Medicine, 2006, 6, 348-351. | 1.9 | 15 |
| 63 | IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy. Journal of Allergy and Clinical Immunology, 2005, 116, 73-79. | 2.9 | 99 |
| 64 | CXCR1+CD4+T Cells in Human Allergic Disease. Journal of Immunology, 2004, 172, 268-273. | 0.8 | 24 |
| 65 | Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. Journal of Immunology, 2004, 172, 3252-3259. | 0.8 | 496 |
| 66 | Mechanisms of immunotherapy. Journal of Allergy and Clinical Immunology, 2004, 113, 1025-1034. | 2.9 | 372 |
| 67 | Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 543-548. | 2.3 | 57 |
| 68 | Tregs and allergic disease. Journal of Clinical Investigation, 2004, 114, 1389-1397. | 8.2 | 235 |
| 69 | Tregs and allergic disease. Journal of Clinical Investigation, 2004, 114, 1389-1397. | 8.2 | 131 |
| 70 | The CX3C chemokine fractalkine in allergic asthma and rhinitis. Journal of Allergy and Clinical Immunology, 2003, 112, 1139-1146. | 2.9 | 82 |
| 71 | Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2003, 112, 915-922. | 2.9 | 266 |
| 72 | Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2003, 111, 1255-1261. | 2.9 | 486 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Immunomodulatory Treatment Strategies for Allergic Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2003, 2, 31-46. | 3.1 | 10 |
| 74 | Treatment of seasonal allergic rhinitis: Desensitisation for hay fever works. <i>BMJ: British Medical Journal</i> , 2003, 327, 1229-1229. | 2.3 | 0 |
| 75 | NHS allergy services in the UK: proposals to improve allergy care. <i>Clinical Medicine</i> , 2002, 2, 122-127. | 1.9 | 21 |
| 76 | Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1&Th2 cytokine ratios. <i>Immunology</i> , 2002, 105, 56-62. | 4.4 | 132 |
| 77 | Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 87-93. | 2.9 | 261 |
| 78 | Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 971-976. | 2.9 | 115 |
| 79 | Allergen Immunotherapy. , 2001, 31, 186-190. | | 0 |
| 80 | T Cell Phenotypes of the Normal Nasal Mucosa: Induction of Th2 Cytokines and CCR3 Expression by IL-4. <i>Journal of Immunology</i> , 2001, 166, 2303-2310. | 0.8 | 17 |
| 81 | Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 293-301. | 2.9 | 49 |
| 82 | T lymphocytes in asthma: Bronchial versus peripheral responses. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, S221-S226. | 2.9 | 36 |
| 83 | Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. <i>New England Journal of Medicine</i> , 1999, 341, 468-475. | 27.0 | 1,256 |
| 84 | Immunologic changes associated with allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 157-164. | 2.9 | 321 |
| 85 | Localization and up-regulation of Mucin (MUC2) gene expression in human nasal biopsies of patients with cystic fibrosis. <i>Journal of Pathology</i> , 1997, 181, 305-310. | 4.5 | 30 |
| 86 | Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon- β . <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 1356-1365. | 2.9 | 383 |
| 87 | Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. <i>Nature Medicine</i> , 1995, 1, 39-46. | 30.7 | 736 |
| 88 | Predominant T _{H2} -like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma. <i>New England Journal of Medicine</i> , 1992, 326, 298-304. | 27.0 | 2,719 |